Back to Search
Start Over
Nano-vesicles based on phospholipid-like amphiphilic polyphosphazenes to orally deliver ovalbumin antigen for evoking anti-tumor immune response
- Source :
- Acta Biomaterialia. 106:267-277
- Publication Year :
- 2020
- Publisher :
- Elsevier BV, 2020.
-
Abstract
- Aimed at evoking an adequate anti-tumor immune response via oral administration route, this study constructed functionally and structurally mimicking-bacteria-membrane (MBM) nano-vesicle (RGD-PEOP) to orally deliver ovalbumin (OVA) antigen. In terms of simulating bacterial membrane structure, we creatively designed this nano-vesicle to have phospholipid-like octadecylphosphoethanolamine groups in vesicle membrane to improve OVA loading by means of specific interactions including salt bridge and hydrogen bond interaction. For simulating bacterial membrane function, the RGD peptide was modified onto the nano-vesicle surface, and the resulting vector displayed a good transport ability with a 3.4-fold higher than free OVA. In vitro and in vivo assay showed that the expression of co-stimulatory molecules and MHC class II complexes was significantly enhanced by MBM nano-vesicle. IFN-γ and IL-4 levels also increased several folds in the MBM nano-vesicle group. Consequently, MBM nano-vesicle achieved the highest in vivo inhibition rate of 69% against E.G7-OVA tumors among all the oral groups. These results suggest that this MBM nano-vesicle may be a promising vector to orally deliver OVA antigen for cancer immunotherapy. STATEMENT OF SIGNIFICANCE: Developing an effective non-bacterial carrier for oral cancer immunotherapy remains challenging. This work constructed a mimicking-bacteria-membrane nano-vesicle based on phospholipid-like amphiphilic polyphosphazenes for oral delivery of ovalbumin antigen. With the considerable capability to load ovalbumin antigen and target M cells, the nano-vesicle produced remarkable tumor suppression in vivo by evoking anti-tumor immune response.
- Subjects :
- CD4-Positive T-Lymphocytes
Ovalbumin
Polymers
medicine.medical_treatment
0206 medical engineering
Biomedical Engineering
Administration, Oral
Antineoplastic Agents
02 engineering and technology
CD8-Positive T-Lymphocytes
Biochemistry
Biomaterials
Surface-Active Agents
Organophosphorus Compounds
Immune system
Cancer immunotherapy
Antigen
In vivo
Oral administration
Cell Line, Tumor
Neoplasms
medicine
Animals
Molecular Biology
Microfold cell
Drug Carriers
Mice, Inbred BALB C
biology
Chemistry
General Medicine
021001 nanoscience & nanotechnology
020601 biomedical engineering
In vitro
Cell biology
Liposomes
biology.protein
Female
Immunotherapy
0210 nano-technology
Biotechnology
Subjects
Details
- ISSN :
- 17427061
- Volume :
- 106
- Database :
- OpenAIRE
- Journal :
- Acta Biomaterialia
- Accession number :
- edsair.doi.dedup.....f9481be16c3962aba9b0d124b932f879
- Full Text :
- https://doi.org/10.1016/j.actbio.2020.02.012